Maravai LifeSciences Q2 Sales $73.400M Beat $71.634M Estimate
Portfolio Pulse from Benzinga Newsdesk
Maravai LifeSciences (NASDAQ:MRVI) reported Q2 sales of $73.4 million, surpassing the analyst consensus estimate of $71.634 million by 2.46%. This marks a 6.51% increase from the same period last year.
August 07, 2024 | 9:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Maravai LifeSciences reported Q2 sales of $73.4 million, beating the analyst consensus estimate of $71.634 million by 2.46%. This represents a 6.51% increase from the same period last year.
The company's Q2 sales exceeded analyst expectations and showed a year-over-year increase, which is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100